<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Vol.

42

No.

37

October 07, 2016Oct 07, 2016

Free

DOWNLOAD THE PDF

With 20 Agents, 803 Trials, and 166,736 Patient Slots, Is Pharma Investing Too Heavily in PD-1 Drug Development?

Cover Story

Free

With 20 Agents, 803 Trials, and 166,736 Patient Slots, Is Pharma Investing Too Heavily in PD-1 Drug Development?

By Laura Brawley

Pharmaceutical companies are betting big on cancer immunotherapies that rely on the PD-1 protein and its ligands, PD-L1 and PD-L2, to initiate an immune response.

Perspectives on Clinical Development of PD-1 Drugs

Conversation with The Cancer Letter Free

Perspectives on Clinical Development of PD-1 Drugs

Recent Issues

Volume 52 | Issue 26 - July 02, 2026

Volume 52 | Issue 25 - June 26, 2026

Volume 52 | Issue 24 - June 18, 2026

Volume 52 | Issue 23 - June 12, 2026

Volume 52 | Issue 22 - June 05, 2026

Volume 52 | Issue 21 - May 29, 2026